Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tetravalent CYD Dengue Vaccine, 5555 formulation · 1 trial · 3 indications
Percentage of participants with antibody titers \>= 10 (1/dil) against each serotypes (1, 2, 3 and 4) of the dengue virus strains was assessed by dengue plaque reduction neutralization test (PRNT).
| Arm | Type | Description |
|---|---|---|
| CYD Dengue Vaccine 5555 Formulation | EXPERIMENTAL | Participants received 3 doses of CYD dengue vaccine (5555 formulation); one each at 0 (vaccination 1), 6 (vaccination 2), and 12 (vaccination 3) months. |
| CYD Dengue Vaccine 5553 Formulation | EXPERIMENTAL | Participants received 3 doses of CYD dengue vaccine (5553 formulation); one each at 0 (vaccination 1), 6 (vaccination 2), and 12 (vaccination 3) months. |
| CYD Dengue Vaccine 4444 Formulation | EXPERIMENTAL | Participants received 3 doses of CYD dengue vaccine (4444 formulation); one each at 0 (vaccination 1), 6 (vaccination 2), and 12 (vaccination 3) months. |
| Name | Type | Description |
|---|---|---|
| Tetravalent CYD Dengue Vaccine , 5555 formulation | BIOLOGICAL | A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively. |
| Tetravalent CYD Dengue Vaccine , 5553 formulation | BIOLOGICAL | A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively |
| Tetravalent CYD Dengue Vaccine, 4444 formulation | BIOLOGICAL | A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively |
Inclusion Criteria: * Healthy, as determined by medical history, clinical examination, and biological safety parameters. * Aged 18 to 45 years on the day of inclusion. * Provision of informed consent signed by the participant or another legally acceptable representative. * For a woman of child-bear...
Tetravalent CYD Dengue Vaccine, 5555 formulation is an investigational vaccine being developed for the prevention of dengue fever, including dengue hemorrhagic fever and infections caused by dengue virus. It is designed for use in healthy adults and is currently in clinical development.
Tetravalent CYD Dengue Vaccine, 5555 formulation is being developed by Sanofi, a global biopharmaceutical company. Sanofi is listed on the stock exchange under the ticker symbol SNY.
Tetravalent CYD Dengue Vaccine, 5555 formulation is in Phase 2 clinical development. It is an investigational vaccine and has not been approved by regulatory authorities. It is being studied for its immunogenicity and safety in healthy adults.
Tetravalent CYD Dengue Vaccine, 5555 formulation has been studied in a Phase 2 clinical trial with the identifier NCT00617344. This trial, titled 'Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US,' enrolled 260 participants in the United States and has been completed.
Tetravalent CYD Dengue Vaccine, 5555 formulation is one of several formulations of dengue vaccines being developed by Sanofi. It is a tetravalent vaccine, meaning it is designed to target multiple serotypes of the dengue virus. Its specific formulation is identified by the designation '5555.'